100% efficacy to ombitasvir/paritaprevir/ritonavir (± dasabuvir) with or without ribavirin in hepatitis C virus genotypes 1 and 4-infected hemodialysis patients

被引：0
|
作者：
Sanai, F. M. [1 ,2 ]
Alghamdi, A. S. [3 ]
Afghani, A. [4 ]
Alswat, K. A. [5 ]
Aseeri, A. [6 ]
Babatin, M. A. [3 ]
机构：
[1] King Abdul Aziz Med City, Dept Med, Gastroenterol Unit, Jeddah, Saudi Arabia
[2] King Saud Univ, Liver Dis Res Ctr, Riyadh, Saudi Arabia
[3] King Fahad Hosp, Dept Med, Gastroenterol Unit, Jeddah, Saudi Arabia
[4] King Fahad Hosp, Dept Med, Gastroenterol Unit, Madinah Al Munawarrah, Saudi Arabia
[5] King Saud Univ, Liver Dis Res Ctr, Dept Med, Gastroenterol Unit, Riyadh, Saudi Arabia
[6] King Fahd Med City, Riyadh, Saudi Arabia
来源：
JOURNAL OF HEPATOLOGY | 2017年 / 66卷 / 01期
关键词：
D O I：
10.1016/S0168-8278(17)30944-3
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THU-277
引用
收藏
页码：S312 / S312
页数：1
相关论文
共 50 条
  • [21] Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients
    Khatri, Amit
    Mensing, Sven
    Podsadecki, Thomas
    Awni, Walid
    Menon, Rajeev
    Dutta, Sandeep
    CLINICAL DRUG INVESTIGATION, 2016, 36 (08) : 625 - 635
  • [22] REAL-WORLD DATAON THE USE OF RIBAVIRIN WITH OMBITASVIR/PARITAPREVIR/R WITH OR WITHOUT DASABUVIR IN HCV GENOTYPE 1 OR 4-INFECTED PATIENTS FROM THE GERMAN HEPATITIS C REGISTRY
    Welzel, T. M.
    Buggisch, P.
    Berg, T.
    Stein, K.
    Hettinger, J.
    Kleine, H.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S826 - S826
  • [23] Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients
    Amit Khatri
    Sven Mensing
    Thomas Podsadecki
    Walid Awni
    Rajeev Menon
    Sandeep Dutta
    Clinical Drug Investigation, 2016, 36 : 625 - 635
  • [24] Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders
    Sonsuz, Abdullah
    Bozcan, Selma
    Hatemi, Ibrahim
    Ozdemir, Sebati
    Canbakan, Billur
    Yildirim, Suleyman
    Gulturk, Ilkay
    Ar, Cem
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2022, 33 (05) : 414 - 420
  • [25] COST-EFFECTIVENESS OF OMBITASVIR/PARITAPREVIR/RITONAVIR WITH OR WITHOUT DASABUVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C PATIENTS INFECTED WITH GENOTYPE 1 OR 4 IN FRANCE
    Sroczynski, G.
    Conrads-Frank, A.
    Muhlberger, N.
    Kuhne, F.
    Jeanblanc, G.
    Samp, J. C.
    Durand-Zaleski, I
    Siebert, U.
    VALUE IN HEALTH, 2016, 19 (07) : A416 - A416
  • [26] Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection
    Danis, Nilay
    Toz, Huseyin
    Unal, Nalan
    Yilmaz, Mumtaz
    Turan, Ilker
    Gunsar, Fulya
    Karasu, Zeki
    Ersoz, Galip
    Ozkahya, Mehmet
    Akarca, Ulus Salih
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2019, 30 (08) : 695 - 701
  • [27] Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2
    Rockstroh, Juergen K.
    Orkin, Chloe
    Viani, Rolando M.
    Wyles, David
    Luetkemeyer, Anne F.
    Lazzarin, Adriano
    Soto-Malave, Ruth
    Nelson, Mark R.
    Bhagani, Sanjay R.
    Klinker, Hartwig H. F.
    Rizzardini, Giuliano
    Girard, Pierre-Marie
    Tural, Cristina
    Shulman, Nancy S.
    Mobashery, Niloufar
    Hu, Yiran B.
    Fredrick, Linda M.
    Pilot-Matias, Tami
    Trinh, Roger
    Gane, Edward
    OPEN FORUM INFECTIOUS DISEASES, 2017, 4 (03):
  • [28] Efficacy and safety of Ombitasvir/Paritaprevir/Ritonavir+ Dasabuvir and Ribavirin in patients with compensated HCV cirrhosis
    Crisu, Georgiana C.
    Ionita-Radu, Florentina
    Costache, Raluca S.
    Balaban, Vasile D.
    Nuta, Petrut
    Stoica, Victor
    Vutcan, L. Oana
    Stefan, Ion
    Naftanaila, Florica Mali
    Jinga, Mariana
    ROMANIAN JOURNAL OF MILITARY MEDICINE, 2019, 122 (01) : 22 - 26
  • [29] Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection
    Perello, C.
    Carrion, J. A.
    Ruiz-Antoran, B.
    Crespo, J.
    Turnes, J.
    Llaneras, J.
    Lens, S.
    Delgado, M.
    Garcia-Samaniego, J.
    Garcia-Paredes, F.
    Fernandez, I.
    Morillas, R. M.
    Rincon, D.
    Porres, J. C.
    Prieto, M.
    Lazaro Rios, M.
    Fernandez-Rodriguez, C.
    Hermo, J. A.
    Rodriguez, M.
    Herrero, J. I.
    Ruiz, P.
    Fernandez, J. R.
    Macias, M.
    Pascasio, J. M.
    Moreno, J. M.
    Serra, M. A.
    Arenas, J.
    Real, Y.
    Jorquera, F.
    Calleja, J. L.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (03) : 226 - 237
  • [30] Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis
    Wedemeyer, H.
    Craxi, A.
    Zuckerman, E.
    Dieterich, D.
    Flisiak, R.
    Roberts, S. K.
    Pangerl, A.
    Zhang, Z.
    Martinez, M.
    Bao, Y.
    Calleja, J. -L.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (11) : 936 - 943
12345